Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 76Carcinoma, Non-Small-Cell Lung 73Multiple Myeloma 58Prostatic Neoplasms 57Colorectal Neoplasms 45Leukemia, Myeloid, Acute 43Neoplasms 41Melanoma 35Lymphoma 35Lung Neoplasms 32Ovarian Neoplasms 31Lymphoma, Non-Hodgkin 30Squamous Cell Carcinoma of Head and Neck 29Sarcoma 28Neoplasm Metastasis 27Pancreatic Neoplasms 26Endometrial Neoplasms 25Carcinoma, Hepatocellular 25Hodgkin Disease 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Large B-Cell, Diffuse 22Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Recurrence 21Urinary Bladder Neoplasms 20Myelodysplastic Syndromes 20Head and Neck Neoplasms 20Esophageal Neoplasms 17Stomach Neoplasms 16

Interventions

pembrolizumab 1enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muscle-invasive Bladder Cancer × 30 days × Clear all
NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡